MONMOUTH JUNCTION, NJ--(Marketwire - September 26, 2008) - TyRx, Inc., a leader in the development and commercialization of convergent drug-device medical products, announced today the launch of AIGISRX™ ICD, an anti-bacterial envelope developed to help stabilize the implanted device and which also contains anti-microbial agents that help provide protection against surgical site infections (SSI) associated with implantable cardioverter defibrillators (ICDs).
